Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QDP201
- Development stage
- Preclinical
- Lead developer
- RestoriT
- Modality
- Small Molecules
01
Overview
QDP201 is an investigational small molecule therapeutic being developed by RestoriT for the treatment of metabolic diseases. The candidate is part of RestoriT's pipeline focused on circadian biology and chronotherapy, which aims to address chronic conditions by restoring natural biological rhythms. Developed based on research into the intersection of the body's internal clock and metabolic health, QDP201 is designed to modulate physiological cycles to improve metabolic dysfunction. As of early 2025, the program is in the early stages of development, and specific details regarding its molecular target remain proprietary.
Beyond the preview
Go deeper on QDP201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QDP201.